Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Myeloid Growth Factors JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Crawford, J., Armitage, J., Balducci, L., Becker, P. S., Blayney, D. W., Cataland, S. R., Heaney, M. L., Hudock, S., Kloth, D. D., Kuter, D. J., Lyman, G. H., McMahon, B., Rugo, H. S., Saad, A. A., Schwartzberg, L. S., Shayani, S., Steensma, D. P., Talbott, M., Vadhan-Raj, S., Westervelt, P., Westmoreland, M., Dwyer, M., Ho, M. 2013; 11 (10): 1266-1290

Abstract

Febrile neutropenia, a common side effect of myelosuppressive chemotherapy in patients with cancer, can result in prolonged hospitalization and broad-spectrum antibiotic use, often prompting treatment delays or dose reductions of drug regimens. Prophylactic use of myeloid growth factors (mainly the colony-stimulating factors filgrastim and pegfilgrastim) in patients of heightened risk can reduce the severity and duration of febrile neutropenia. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors provide recommendations on the use of these agents mainly in the oncology setting based on clinical evidence and expert consensus. This version includes revisions surrounding the issue of timing of pegfilgrastim administration. It also includes new sections on tbo-filgrastim, a recently approved agent that is biologically similar to filgrastim, and the role of myeloid growth factors in the hematopoietic cell transplant setting.

View details for Web of Science ID 000325929600010

View details for PubMedID 24142827